

Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia

Galešić, Krešimir; Božić, Borka; Račić, Ivana; Šćukanec-Špoljar, Mira

Source / Izvornik: **Nephrology**, 2006, 11, 49 - 52

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1111/j.1440-1797.2006.00524.x>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:588788>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-05-26**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)





Središnja medicinska knjižnica

Galešić, K., Božić, B., Račić, I., Šćukanec-Špoljar, M. (2006) *Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia*. *Nephrology*, 11 (1). pp. 49-52.

The definitive version is available at www.blackwell-synergy.com.
<http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1797.2006.00524.x>

<http://medlib.mef.hr/258>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

Thrombotic Microangiopathy Associated with α -Interferon Therapy for Chronic Myeloid Leukemia

Kresimir Galesic (1), Borka Bozic(1), Ivana Racic (1), Mira Scukanec-Spoljar (2)

(1) Department of Medicine, Dubrava University Hospital, Zagreb Medical School

(2) Department of Pathology, Zagreb Medical School

Kresimir Galesic M.D. Ph.D.

Dubrava University Hospital

Zagreb 10000, Croatia

Av. G. Suska 6

Tel. 385 (1) 2903491. Fax 385 (1) 2903481

E-mail. kresog@zagreb.kbd.hr

ABSTRACT

The association of interferon therapy with hemolytic uremic syndrome in patients with chronic myeloid leukemia (CML) has been reported infrequently. The pathogenesis of the renal lesion in such cases remains unclear. We report the case of a patient with chronic myeloid leukemia who developed nephrotic syndrome and renal failure while being treated with hydroxyurea and interferon- α . Renal biopsy showed features of chronic thrombotic microangiopathy. The discontinuation of interferon- α , and a prompt institution of plasmapheresis and steroids resulted in improvement of the nephrotic syndrome and renal function. These findings suggest that long-term interferon- α therapy can induce thrombotic microangiopathy and hemolytic uremic syndrome in patients with chronic myeloid leukemia.

Key words: chronic myeloid leukemia, interferon, nephrotic syndrome, renal failure, thrombotic microangiopathy.

INTRODUCTION

Therapy for chronic myeloid leukemia (CML) consists of cytoreduction (typically with hydroxyurea) and interferon- α : only a minority undergo bone marrow transplantation. Only a few reports of renal thrombotic microangiopathy have been described in patients with CML. In almost all cases these patients were receiving interferon- α (1-6). The interferons are a family of glycoproteins with antiviral, antitumor and immunomodulatory activities. Interferon- α is used particularly in the treatment of chronic myeloid leukemia, and other haematological malignancies as well as in hepatitis C. Various adverse effects associated with interferon- α have been reported previously, including cardiac and renal dysfunction (7). In patients with chronic hepatitis C, interferon- α therapy is rarely associated with renal side effects (8). In patients receiving high doses of interferon- α for malignancy, a wide range of renal side effects have been reported, including proteinuria, acute interstitial nephritis and membranoproliferative glomerulonephritis (9-12). In some cases, the discontinuation of treatment led to the recovery of renal function, but irreversible renal failure may occur (4-6). Many authors have observed various renal toxicities with interferon- α therapy, but the incidence of renal complications remains unknown and the causal link between interferon- α and thrombotic microangiopathy is still underappreciated. We described a case of haemolytic uremic syndrome that occurred in a patient with CML receiving interferon- α and hypotheses regarding the potential mechanisms underlying this association are discussed.

CASE REPORT

A 45-year-old man was admitted in July 2001 because of increased leukocytes and platelets. Previous medical history was unremarkable. Physical examination showed hepatosplenomegaly. The peripheral blood leukocytes count was $43 \times 10^9/L$, Hb 111 g/L, platelets 1209×10^9 , serum creatinine was $88 \mu\text{mol/L}$, urinalysis was normal. The bone marrow biopsy was diagnostic of CML and the presence of the Philadelphia chromosome. Treatment included hydroxyurea (50mg/kg/day) and interferon- α (Roferon) 9×10^6 IU

subcutaneously/day and allopurinol 100mg/day. One year later his peripheral leukocytes count had decreased to 18.1×10^9 , and platelets to 457×10^9 . Hepatosplenomegalia had regressed. In August the patient was referred to Nephrology department for edema and a recently discovered impairment of renal function (serum creatinine $450 \mu\text{mol/L}$). On admission he was pale, had high blood pressure (190/120 mmHg), bibasal lung crackles, hepatosplenomegaly, and marked lower limb edema. Urinary dipstick showed protein ++, trace red cells, microscopy showed a few granular casts only. Ultrasound showed normal sized kidneys with echogenic cortex. Severe anemia with a hemoglobin level of 49 g/dl was present, hematocrit was 0.33, mean corpuscular volume 0,93fl and reticulocyte count was 1,2%. He had the following results: WBC 4.9×10^9 platelets 128×10^9 , total bilirubin 17 $\mu\text{mol/L}$ (reference range 3.4-20.5 $\mu\text{mol/L}$) lactate dehydrogenase (LDH) 2845 U/L (reference range 170-430 U/L), Coombs test-indirect was positive, normal liver enzymes, creatinine 450 $\mu\text{mol/L}$ (reference range 64-120 $\mu\text{mol/L}$). The following tests were negative or normal: antinuclear antibody (ANA), hepatitis B, surface antigen (HbsAg) hepatitis B core antibody (HbcAb) human immunodeficiency virus antibody (HIV), prothrombin time (PT) partial thromboplastin time (PTT), serum fibrinogen, fibrin split products and serum haptoglobin. Serum C3 were depressed at 0,57 (reference range, 0.9-1.8g/L) serum C4 was 0.12g/L (reference range 0.1-to 4.0 g/L). A peripheral blood smear revealed moderate schistocytosis. Serum protein electrophoresis was normal, proteinuria was 16.2 g/day (normal value $<0.2\text{g/day}$). Bone marrow biopsy revealed a CML. Fundoscopy detected a stage II retinopathy

Percutaneous renal biopsy disclosed typical changes of thrombotic microangiopathy: by light microscopy all glomeruli (20 glomeruli) were globally enlarged. The remainder showed increased mesangial matrix cells and pronounced thickening of peripheral capillary loops (Figure 1). Diffuse subendothelial swellings of the glomerular capillary walls coexisted with focal thrombi of the capillary lumen and of the arterioles whose intima was extensively swollen.

The latter finding was associated with marked «double contour» formation (duplication of the basement membrane) and with interposition of cell elements within the thickened capillary walls. Many of the glomerular capillaries were occluded by the thickened walls and swollen endothelial cells. Significant interstitial fibrosis was also present. The smaller arteries and arterioles showed marked fibrocellular proliferation with myxoid change and focal hyaline deposition, often resulting in significant narrowing of vessel lumen. Immunofluorescence microscopy showed large granular deposits of immunoglobulin M (IgM) and fibrin. Electron

microscopy showed extensive capillary wall changes with degenerative change of the endothelium and loss of fenestrae; there was widening of the subendothelium space by electron-lucent material and by cellular projections and formation of the new basement membrane under displaced endothelial cells (Figure 2). The light and electron microscopy findings were highly suggestive of thrombotic microangiopathy.

A diagnosis of HUS was made and the patient was started on daily plasmapheresis (7 days). The patient was also given corticosteroids, aspirin and antihypertensives. Renal function improved and stabilized with serum creatinine of 200 μ mol/l. His Hb increased to 100g/L. Interferon- α was withdrawn and oral hydroxyurea was continued for management of the CML. The patient was seen for his outpatient control one and two months later. His renal function was improving (creatinine 170 μ mol/l) and CML in stable phase.

DISCUSSION

The mechanisms by which interferon- α therapy may initiate HUS are unknown, but several mechanisms are possible. Interferon- α has been shown to increase leukocyte adherence to vascular endothelium, and this may initiate endothelial cell damage and subsequent release of large multimers of the von Willebrand factor, causing endothelial cell swelling, platelet aggregation and intraluminal microthrombi formation. Unusually large multimers of von Willebrand factor are probably cleaved by metalloprotease-ADAMTS 13 directly on the surface of endothelial cells. Some of the patients with hemolytic-uremic syndrome have a deficiency or defect of complement factor H (13). It will be useful to measure antibodies of ADAMTS 13 and antibodies of H factor, which could better illustrate the mechanism of HUS in our patient, but we could not measure it. Some authors suggested that activated leukocytes and/or their products, such as TNF, IFN, IL-1 and free radicals can participate in tissue injury and endothelial cell damage with the resulting deleterious effects (14). Indeed, in an experimental model of HUS a central role for leukocytes or leukocyte products had been suggested and in vivo neutralisation of TNF or IFN with a specific antiserum protected mice from an HUS-like reaction (15). Therefore, IFN-induced free radicals production by activated phagocytes may result in the pathogenesis of HUS. Another report showed increased IFN production in two patients with HUS associated with adenovirus infection and a possible nephrotoxic role from elevated IFN levels was speculated (16).

Possible nephrotoxic effects of IFN have been previously reported. Exogenous interferons could cause similar effects.

The possible role of interferon- α inducing this toxic effect is increasingly suspected as more case reports are described. In our patient, the clinical presentation and laboratory findings are consistent with the diagnosis of thrombotic microangiopathy and renal dysfunction and the presence of schistocytes in the blood smear were detected. Platelets in our patient were slightly decreased (platelets 128×10^9).

Because renal failure was predominant feature at presentation of our patient this disorder was considered to be the haemolytic-uremic syndrome. The clinical distinction between thrombotic thrombocytopenic purpura and haemolytic-uremic syndrome is not always clear (14). Treatment with interferon- α was probably the only factor involved in the development of HUS. No other known causes could be suspected in our patient.

The subsidence of HUS after the cessation of interferon therapy strongly supports the view that interferon caused HUS in our patient.

HUS has already been reported during treatment with a number of cytotoxic agents (mitomycin, methyl-carmustin, bleomycin, daunomycin, cisplatin, and deoxycoformycin) but has never to date been described with hydroxyurea, suggesting a role for interferon- α .

The association of interferon- α therapy with hemolytic uremic syndrome and thrombotic thrombocytopenic purpura has been reported infrequently. Only sporadic cases of HUS have been reported in association with interferon treatment in CML (1-6).

HUS is a rare side effect that occurs in only small subgroup of patients given interferon- α for CML. There is a possible genetical predisposition in these patients. Several studies have demonstrated genetic predisposition in non-shigatoxin-associated hemolytic uremic syndrome, involving regulatory proteins of the complement alternative pathway: factor H and membrane co-factor protein (CD46) (17).

The association of malignant disorders and cancer chemotherapeutic agents with hemolytic uremic syndrome (HUS) and thrombotic microangiopathy (TTP) has been previously described (18, 19). Most cases occur in patients with adenocarcinomas, gastric adenocarcinoma being the most common, but also with small lung carcinoma, squamous carcinoma and Hodgkin disease. CML has been uncommonly associated with microangiopathic disorders (20, 21, 22). In HUS, renal endothelial cell injury, with endothelial cell swelling and the resulting narrowing of the glomerular capillary lumen, is believed to be the initiating event. HUS is commonly preceded by bloody diarrhea caused by infectious organisms, such as *Shigella dysenteriae* or *E. coli*. The toxins secreted by these organisms, are capable of

binding the predominant membrane globotrisyl ceramide (Gb3). Gb3 is expressed on the membrane of renal endothelial cells and other endothelial cells. Other agents can up-regulate Gb3 expression on the endothelial cells and therefore potentiate the effects of the toxins. These include the cytokines interleukin (IL-1) or alpha or beta tumor necrosis factor (TNF)-alpha or beta (18).

The pathogenesis of HUS in Shigella infection is similar to HUS caused with interferon- α . The damage of glomerular endothelial cells by Shiga toxin 1 and 2 is potentiated by the monocytes and neutrophils that invade glomeruli in response to the secreted interleukin-8 and the production of monocytes chemoattractant protein 1 by renal cells. Interleukin-8-activated neutrophils release oxygen-derived free radicals, hydrogen peroxide, elastase and other protease that potentiate the damage to the kidneys. In fact, neutrophilia increases the likelihood of irreversible renal injury. The death and desquamation of endothelial cells in the kidneys may also promote, by means of glycoproteins Iba, the adhesion of platelets to unusually large multimers of von Willibrand factor in the subendothelium. Subsequent binding of fibrinogen to activated platelet glycoprotein IIb/IIIa complexes induces the aggregation of platelets under conditions of high flow as occur in the glomerular microcirculation

In summary, HUS is a rare side effect of interferon- α therapy in patients with CML. The mechanisms contributing to its pathogenesis are poorly understood but interferon- α can through modulatory effects on endothelial receptors make these cells more susceptible to the effects of bacteria toxins. They may also mediate free radical production by activating phagocytic cells and as a result cause endothelial cell injury. The release of platelet-aggregating agents from the damaged endothelial cells is probably the event resulting in intraluminal thrombus formation and organ damage, as seen in HUS. This rare but definite complication of interferon- α therapy should be recognised early when clinical and laboratory findings are suggestive so interferon- α therapy can be discontinued immediately and appropriate therapeutic measures can be initiated.

REFERENCES

1. Honda K, Ando A, Endo M et al. Thrombotic Microangiopathy Associated With Alpha-Interferon Therapy for Chronic Myelocytic Leukemia. Am J Kidney Dis 1997;39:123-130

2. Rachmani R, Avigdor A, Youkla M et al. Thrombotic Thrombocytopenic Purpura Complicating Chronic Myelogenous Leukemia Treated with Interferon- α . *Acta Hematol* 1998;100:204-206
3. Magee CC, Abraham K, Farrell J et al. Renal Thrombotic Microangiopathy Associated With Interferon- α Treatment of Chronic Myelocytic Leukemia. *Am J Kidney Dis* 200;36: E5
4. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjan HM. Thrombotic Microangiopathy Associated With Interferon Therapy for Patients with Chronic Myelocytic Leukemia. *Cancer* 1999;85:2583-8
5. Jadou M, Piessevaux H, Ferreant A, Cosyns JP, van Ypersele de Strihou. Renal thrombotic microangiopathy in pateints with chronic myelogenous leukemia treated with interferon- α 2b. *Nephrol Dial Transplant* 1995;10:111-113
6. Badid C, McGregor B, Faivre MJ et al. Renal thrombotic microangiopathy induced by interferon- α . *Nephrol Dial Transplant* 2001;16:846-848
7. Vial T, Descotes J. Clinical toxicity of the interferons. *Drug Safety* 1994;10:115-150
8. Ubara Y, Hara S, Takedata H et al. Hemolytic Uremic syndrome Associated with β -Interferon Therapy for Chronic Hepatitis C. *Nephron* 1998;80:107-108
9. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. *J Clin Oncol* 1986;4:234-243
10. Averbuch SD, Austin HA, Sherwin SA. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocytes A interferon therapy for mycosis fungoides. *N Engl J Med* 1984;310:32-35
11. Herman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. *N Engl J Med* 1987;316:112-113
12. Shah M, Jenis EH, Mookerje BK et al. Intereferon- α associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. *Cancer* 1998;83:1938-1946
13. Warwicker P, Donne RL, Goodship JA et al. Genetic studies into inheretited and sporadic hemolytic uremic syndrome. *Kidney Int* 1998;53:836-44
14. Harvey M, Rosenfeld D, Davies D, Hall BM. Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincedence? *Am J Hamatol* 1994;47:254-253
15. Butler T, Rahman H, Ali-Mahmud K et al. An animal model of haemolytic uremic syndrome in shigellosis: liposaccharides of shiella dysenteriae I and shigella flexneri produce leukocyte-mediated renal cortical necrosis in rabbits. *Br J Exp Pathol* 1985;66:7-15

16. Blachr Y, Leibovitz E, Levin S. The interferon system in two patients with hemolytic syndrome associated with adenovirus infection. *Acta Paediatr Scand* 1990;79:108-9
17. Dragon-Durey MA, Loiret C, Cloarec S et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2005;16:555-63
18. Lipton JH, Minden M. CML may not be part of HUS. *Am J Hematol* 1995;49:100-101
19. Moake JL. Thrombotic Microangiopathies. *N Engl J Med* 2002;347:589-600
20. Shammash F, Meyer P, Heikkila R et al. Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. *Acta Hematol* 1997;97:184-186
21. Gordon IJ, Kwaan HC. Cancer and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Semin Hematol* 1997;34:140-147
22. Bennet CI, Weinberg PD, Rozenberg-Ben-Dror K et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. *Ann Intern Med* 1998;128:541-544

Figure 1. Haemolytic-uremic syndrome. A large glomerulus with inconspicuous mesangium because of mesangiolysis. Capillaries are dilated, some filled with thrombi and some have split, double contoured basement membranes. P.A.S. method. 400x




Figure 2. An ultrastructural detail of a glomerulus. One can see the detachment of endothelial cells from GBM with formation of the clear space filled with some fluffy material. Uranyl-acetate and lead cytrate. 24500

